Abstract Introduction: Diazoxide is the first-line treatment used to manage infants and children with hypoglycemia secondary to hyperinsulinemic hypoglycemia (HH), after initial stabilization of blood glucose. Recent changes in Pediatric Endocrine Society guidelines regarding definition of, and screening for hypoglycemia in the neonate led to an increase in the number of infants treated with diazoxide. Previous studies have noted various side effects of diazoxide. With the increased use of this drug in neonates, our aim is to further evaluate these side effects. Methods: We performed a retrospective case control analysis of all neonates admitted to a tertiary care center in New Jersey who were treated with diazoxide for hypoglycemia after a...
Persistent hyperinsulinemic hypoglycemia of infancy (PHHI), also known as congenital hyperinsulinism...
Diazoxide is the first-line treatment for patients with hyperinsulinaemic hypoglycaemia (HH). Approx...
Diuretics are often prescribed off-label to premature infants, particularly to prevent or treat bron...
Abstract Introduction: Diazoxide is the first-line treatment used to manage infants and children wit...
Hypoglycemia in neonates is associated with long-term neurodevelopmental effects. Hyperinsulinemic h...
Diazoxide is one of the FDA-approved pharmacologic treatments for hyperinsulinemic hypoglycemia, how...
Pharmacologic modulation to open the KATP channels with diazoxide is useful in treating hyperinsulin...
SUMMARY Seven infants with persistent neonatal hyperinsulinism were treated in Dhahran Health Centre...
Background: Diazoxide is the main therapeutic agent for congenital hyperinsulinism. The drug is gene...
PubMedID: 18512033Primary persistent hyperinsulinaemic hypoglycaemia is characterised by clinical sy...
<p><b><i>Background:</i></b> Diazoxide is the first-line treatment for pediatric hyperinsulinemic h...
Primary persistent hyperinsulinaemic hypoglycaemia of infancy is rare. Diazoxide treatment remains t...
Recalcitrant neonatal hypoglycemia poses a treatment challenge for clinicians. When a patient's hypo...
WOS: 000418709600016Hyperinsulinemic hypoglycemia (HH) is the most common reason for persistent and ...
Diazoxide is the first-line drug for treating hyperinsulinism and the only pharmacological agent app...
Persistent hyperinsulinemic hypoglycemia of infancy (PHHI), also known as congenital hyperinsulinism...
Diazoxide is the first-line treatment for patients with hyperinsulinaemic hypoglycaemia (HH). Approx...
Diuretics are often prescribed off-label to premature infants, particularly to prevent or treat bron...
Abstract Introduction: Diazoxide is the first-line treatment used to manage infants and children wit...
Hypoglycemia in neonates is associated with long-term neurodevelopmental effects. Hyperinsulinemic h...
Diazoxide is one of the FDA-approved pharmacologic treatments for hyperinsulinemic hypoglycemia, how...
Pharmacologic modulation to open the KATP channels with diazoxide is useful in treating hyperinsulin...
SUMMARY Seven infants with persistent neonatal hyperinsulinism were treated in Dhahran Health Centre...
Background: Diazoxide is the main therapeutic agent for congenital hyperinsulinism. The drug is gene...
PubMedID: 18512033Primary persistent hyperinsulinaemic hypoglycaemia is characterised by clinical sy...
<p><b><i>Background:</i></b> Diazoxide is the first-line treatment for pediatric hyperinsulinemic h...
Primary persistent hyperinsulinaemic hypoglycaemia of infancy is rare. Diazoxide treatment remains t...
Recalcitrant neonatal hypoglycemia poses a treatment challenge for clinicians. When a patient's hypo...
WOS: 000418709600016Hyperinsulinemic hypoglycemia (HH) is the most common reason for persistent and ...
Diazoxide is the first-line drug for treating hyperinsulinism and the only pharmacological agent app...
Persistent hyperinsulinemic hypoglycemia of infancy (PHHI), also known as congenital hyperinsulinism...
Diazoxide is the first-line treatment for patients with hyperinsulinaemic hypoglycaemia (HH). Approx...
Diuretics are often prescribed off-label to premature infants, particularly to prevent or treat bron...